FDA Adds Warning Label To Obesity Drugs For Eye Condition

The US Food and Drug Administration will now require GLP-1 drugs including Novo's Wegovy and Ozempic and Lilly's Mounjaro, Zepbound and Foundayo to carry warnings that they may increase the risk of non-arteritic anterior ischemic optic neuropathy, or NAION.